Observational studyRheumatology (Oxford, England)2015
Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort.
Open access · hybridAbstract readMulticenter StudyObservational Study
In one paragraph
Observational study in Rheumatology (Oxford, England), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed, 3 pooled it
5.0field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 3 syntheses or guidelines pooled it, 104 citations in OpenAlex.
- Adherence to Hidradenitis Suppurativa Treatment.American journal of clinical dermatology · 2024Pooled it
- Adherence to the antirheumatic drugs: a systematic review and meta-analysis.Frontiers in medicine · 2024Pooled it
- A Targeted Literature Review Examining Biologic Therapy Compliance and Persistence in Chronic Inflammatory Diseases to Identify the Associated Unmet Needs, Driving Factors, and Consequences.Advances in therapy · 2018Pooled it
- Consistent adherence to biologic therapies is critical for improving outcomes in asthma.The journal of allergy and clinical immunology. Global · 2026Article
- Persistence Among Biologic/JAKi-Naive Medicare Beneficiaries with RA Initiating Synthetic DMARDs.Rheumatology and therapy · 2026Article
- Podcast: Adherence to Injectables.Dermatology and therapy · 2026Review
- Effectiveness of Tofacitinib in Patients with Psoriatic Arthritis Initiating Monotherapy Versus Combination Therapy: Results from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry.Rheumatology and therapy · 2026Article
- Comparative Effectiveness of Abatacept Versus Adalimumab in Shared Epitope Positive and Negative Patients With Rheumatoid Arthritis.Arthritis & rheumatology (Hoboken, N.J.) · 2026Article
- Pharmacogenomics of TNF inhibitors.Frontiers in immunology · 2025Review
- An Exploratory Study of Factors Associated with Medication Adherence in Chinese Rheumatoid Arthritis Patients.Journal of inflammation research · 2025Article
- Beliefs of Moroccan patients with chronic inflammatory rheumatic diseases regarding medication: related factors and correlation with therapeutic adherence.BMC rheumatology · 2024Article
- Estimation of optimal adherence threshold for tumor necrosis factor inhibitors in rheumatoid arthritis.Clinical rheumatology · 2024Article
- Satisfaction with the Injection Experience of a New, Citrate-Free Formulation of Ixekizumab.Advances in therapy · 2024Observational
- Using Electronic Health Records and Linked Claims Data to Assess New Medication Use and Primary Nonadherence in Rheumatology Patients.Arthritis care & research · 2024Article
- Towards Personalized Medicine in Rheumatoid Arthritis.Open access rheumatology : research and reviews · 2024Review
- Psoriatic arthritis: the role of self-reported non-adherence, non-trough drug levels, immunogenicity and conventional synthetic DMARD co-therapy in adalimumab and etanercept response.Rheumatology advances in practice · 2024Article
- Non-trough serum drug levels of adalimumab and etanercept are associated with response in patients with psoriatic arthritis.Rheumatology (Oxford, England) · 2023Article
- Non-trough adalimumab and certolizumab drug levels associated with a therapeutic EULAR response in adherent patients with rheumatoid arthritis.Rheumatology (Oxford, England) · 2023Observational
- Development of a sensitive biochemical assay for the detection of tofacitinib adherence.Analytical methods : advancing methods and applications · 2023Article
- Continuity of Care Within a Single Patient Support Program for Patients with Rheumatoid Arthritis Prescribed Second or Later Line Advanced Therapy.Advances in therapy · 2023Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
James BluettArthritis Research UK Centre for Genetics and Genomics, University of Manchester, National Institute of Health Research Manchester Musculoskeletal Biomedical Research Unit, Central Manchester Foundation Trust and University of Manchester, Manchester Academic Health Science, Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, National Institute of Health Research Leeds Musculoskeletal Biomedical Research Unit, Leeds, Academic Unit of Rheumatology, Department of Infection and Immunity, University of Sheffield Medical School, Sheffield, Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle University and National Institute of Health Research Newcastle Biomedical Research Centre, Newcastle upon Tyne and Institute for Inflammation and Repair, University of Manchester, Manchester, UK.
Catharine MorganArthritis Research UK Centre for Genetics and Genomics, University of Manchester, National Institute of Health Research Manchester Musculoskeletal Biomedical Research Unit, Central Manchester Foundation Trust and University of Manchester, Manchester Academic Health Science, Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, National Institute of Health Research Leeds Musculoskeletal Biomedical Research Unit, Leeds, Academic Unit of Rheumatology, Department of Infection and Immunity, University of Sheffield Medical School, Sheffield, Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle University and National Institute of Health Research Newcastle Biomedical Research Centre, Newcastle upon Tyne and Institute for Inflammation and Repair, University of Manchester, Manchester, UK.
Layla ThurstonArthritis Research UK Centre for Genetics and Genomics, University of Manchester, National Institute of Health Research Manchester Musculoskeletal Biomedical Research Unit, Central Manchester Foundation Trust and University of Manchester, Manchester Academic Health Science, Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, National Institute of Health Research Leeds Musculoskeletal Biomedical Research Unit, Leeds, Academic Unit of Rheumatology, Department of Infection and Immunity, University of Sheffield Medical School, Sheffield, Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle University and National Institute of Health Research Newcastle Biomedical Research Centre, Newcastle upon Tyne and Institute for Inflammation and Repair, University of Manchester, Manchester, UK.
Darren PlantArthritis Research UK Centre for Genetics and Genomics, University of Manchester, National Institute of Health Research Manchester Musculoskeletal Biomedical Research Unit, Central Manchester Foundation Trust and University of Manchester, Manchester Academic Health Science, Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, National Institute of Health Research Leeds Musculoskeletal Biomedical Research Unit, Leeds, Academic Unit of Rheumatology, Department of Infection and Immunity, University of Sheffield Medical School, Sheffield, Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle University and National Institute of Health Research Newcastle Biomedical Research Centre, Newcastle upon Tyne and Institute for Inflammation and Repair, University of Manchester, Manchester, UK.
Kimme L HyrichArthritis Research UK Centre for Genetics and Genomics, University of Manchester, National Institute of Health Research Manchester Musculoskeletal Biomedical Research Unit, Central Manchester Foundation Trust and University of Manchester, Manchester Academic Health Science, Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, National Institute of Health Research Leeds Musculoskeletal Biomedical Research Unit, Leeds, Academic Unit of Rheumatology, Department of Infection and Immunity, University of Sheffield Medical School, Sheffield, Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle University and National Institute of Health Research Newcastle Biomedical Research Centre, Newcastle upon Tyne and Institute for Inflammation and Repair, University of Manchester, Manchester, UK.
Ann W MorganArthritis Research UK Centre for Genetics and Genomics, University of Manchester, National Institute of Health Research Manchester Musculoskeletal Biomedical Research Unit, Central Manchester Foundation Trust and University of Manchester, Manchester Academic Health Science, Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, National Institute of Health Research Leeds Musculoskeletal Biomedical Research Unit, Leeds, Academic Unit of Rheumatology, Department of Infection and Immunity, University of Sheffield Medical School, Sheffield, Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle University and National Institute of Health Research Newcastle Biomedical Research Centre, Newcastle upon Tyne and Institute for Inflammation and Repair, University of Manchester, Manchester, UK.
Anthony G WilsonArthritis Research UK Centre for Genetics and Genomics, University of Manchester, National Institute of Health Research Manchester Musculoskeletal Biomedical Research Unit, Central Manchester Foundation Trust and University of Manchester, Manchester Academic Health Science, Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, National Institute of Health Research Leeds Musculoskeletal Biomedical Research Unit, Leeds, Academic Unit of Rheumatology, Department of Infection and Immunity, University of Sheffield Medical School, Sheffield, Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle University and National Institute of Health Research Newcastle Biomedical Research Centre, Newcastle upon Tyne and Institute for Inflammation and Repair, University of Manchester, Manchester, UK.
John D IsaacsArthritis Research UK Centre for Genetics and Genomics, University of Manchester, National Institute of Health Research Manchester Musculoskeletal Biomedical Research Unit, Central Manchester Foundation Trust and University of Manchester, Manchester Academic Health Science, Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, National Institute of Health Research Leeds Musculoskeletal Biomedical Research Unit, Leeds, Academic Unit of Rheumatology, Department of Infection and Immunity, University of Sheffield Medical School, Sheffield, Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle University and National Institute of Health Research Newcastle Biomedical Research Centre, Newcastle upon Tyne and Institute for Inflammation and Repair, University of Manchester, Manchester, UK.
Lis CordingleyArthritis Research UK Centre for Genetics and Genomics, University of Manchester, National Institute of Health Research Manchester Musculoskeletal Biomedical Research Unit, Central Manchester Foundation Trust and University of Manchester, Manchester Academic Health Science, Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, National Institute of Health Research Leeds Musculoskeletal Biomedical Research Unit, Leeds, Academic Unit of Rheumatology, Department of Infection and Immunity, University of Sheffield Medical School, Sheffield, Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle University and National Institute of Health Research Newcastle Biomedical Research Centre, Newcastle upon Tyne and Institute for Inflammation and Repair, University of Manchester, Manchester, UK. lis.cordingley@manchester.ac.uk.
Anne BartonArthritis Research UK Centre for Genetics and Genomics, University of Manchester, National Institute of Health Research Manchester Musculoskeletal Biomedical Research Unit, Central Manchester Foundation Trust and University of Manchester, Manchester Academic Health Science, Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, National Institute of Health Research Leeds Musculoskeletal Biomedical Research Unit, Leeds, Academic Unit of Rheumatology, Department of Infection and Immunity, University of Sheffield Medical School, Sheffield, Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle University and National Institute of Health Research Newcastle Biomedical Research Centre, Newcastle upon Tyne and Institute for Inflammation and Repair, University of Manchester, Manchester, UK. Arthritis Research UK Centre for Genetics and Genomics, University of Manchester, National Institute of Health Research Manchester Musculoskeletal Biomedical Research Unit, Central Manchester Foundation Trust and University of Manchester, Manchester Academic Health Science, Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, National Institute of Health Research Leeds Musculoskeletal Biomedical Research Unit, Leeds, Academic Unit of Rheumatology, Department of Infection and Immunity, University of Sheffield Medical School, Sheffield, Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle University and National Institute of Health Research Newcastle Biomedical Research Centre, Newcastle upon Tyne and Institute for Inflammation and Repair, University of Manchester, Manchester, UK.
BRAGGSS
NIHR Manchester Biomedical Research Centre · GB
Funding
Arthritis Research UK 20385Medical Research Council G1000417Medical Research Council G1000417/94909Medical Research Council G1001518Medical Research Council MR/K015346/1Medical Research Council MR/L01629X/1
Abstract
objectiveNon-adherence to DMARDs is common, but little is known about adherence to biologic therapies and its relationship to treatment response. The purpose of this study was to investigate the association between self-reported non-adherence to s.c. anti-TNF therapy and response in individuals with RA.
methodsParticipants about to start s.c. anti-TNF therapy were recruited to a large UK multicentre prospective observational cohort study. Demographic information and disease characteristics were assessed at baseline. Self-reported non-adherence, defined as whether the previous due dose of biologic therapy was reported as not taken on the day agreed with the health care professional, was recorded at 3 and 6 months following the start of therapy. The 28-joint DAS (DAS28) was recorded at baseline and following 3 and 6 months of therapy. Multivariate linear regression was used to examine these relationships.
resultsThree hundred and ninety-two patients with a median disease duration of 7 years [interquartile range (IQR) 3-15] were recruited. Adherence data were available in 286 patients. Of these, 27% reported non-adherence to biologic therapy according to the defined criteria at least once within the first 6-month period. In multivariate linear regression analysis, older age, lower baseline DAS28 and ever non-adherence at either 3 or 6 months from baseline were significantly associated with a poorer DAS28 response at 6 months to anti-TNF therapy.
conclusionPatients with RA who reported not taking their biologic on the day agreed with their health care professional showed poorer clinical outcomes than their counterparts, emphasizing the need to investigate causes of non-adherence to biologics.
Indexed as
Patient ComplianceArthritis, RheumatoidBiological ProductsCohort StudiesDose-Response Relationship, DrugFemaleFollow-Up StudiesHumansInjections, SubcutaneousLinear ModelsMaleMiddle AgedOutcome Assessment, Health CareProspective StudiesSelf ReportTreatment OutcomeBiological ProductsTumor Necrosis Factor-alphaadherencebehaviourbiologic therapiesoutcome measuresrheumatoid arthritis
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.